FDA clears Empatica’s platform for Parkinson’s monitoring
August 19, 2026
Empatica’s platform enables continuous tracking of symptoms such as bradykinesia, dyskinesia and sleep quality.
Empatica’s platform enables continuous tracking of symptoms such as bradykinesia, dyskinesia and sleep quality.
The approval covers smartSedLine monitor availability in applicable European markets.
WUXI, China, Aug. 19, 2026 /PRNewswire/ — NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORROY’s 68Ga-NYM096, a potential radiopharmaceutical imaging agent targeting carbonic anhydrase Ⅸ (CAⅨ) for PET imaging of clear cell renal cell carcinoma (ccRCC).
BOSTON, Aug. 19, 2026 /PRNewswire/ — Empatica, a leader in digital biomarker development and clinical-grade wearable technology, today announced that the Empatica Health Monitoring Platform for Parkinson’s has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Filing targets TPN, propofol and other IV therapies where undetected infiltration
and extravasation can cause severe injury
Expanded indication enables clinicians to detect sarcopenia risk from the same rapid SOZO scan, supporting earlier intervention in cancer care.
Lantheus’s radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology.
OncoSil’s device is designed for implantation into solid tumours via injection under endoscopic ultrasound guidance.
Johnson & Johnson MedTech (NYSE: JNJ) today announced the launch of Monarch Quest 3, the latest software iteration for its Monarch robotically assisted bronchoscopy platform.
BALTIMORE, Aug. 14, 2026 /PRNewswire/ — Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá.